v3.26.1
Note 2 - Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2026
Notes Tables  
Intangible Asset, Finite-Lived [Table Text Block]
  

Useful Life

 

Purchase

 

Purchase

  

Accumulated

  

Carrying

 

Intangible assets as of June 30, 2026

 

(In years)

 

Date

 

Price

  

Amortization

  

Value

 

Carglumic Acid

  10 

November 2021

 $3,250  $1,517  $1,733 

Betaine

  5 

September 2022

  2,125   1,611   514 

Nitisinone

  5 

October 2023

  650   357   293 

GoLike

  10 

March 2024

  1,868   420   1,448 

Increlex

  10 

December 2024

  21,250   3,263   17,987 

Galzin

  10 

December 2024

  8,119   1,218   6,901 

IPR&D asset

    

January 2026

  1,000      1,000 

Hemangeol

  10 

February 2026

  12,969   432   12,537 

Impavido

  10 

May 2026

  3,304   39   3,265 
       $54,535  $8,857  $45,678 
  

Useful Life

 

Purchase

 

Purchase

  

Accumulated

  

Carrying

 

Intangible assets as of December 31, 2025

 

(In years)

 

Date

 

Price

  

Amortization

  

Value

 

Carglumic Acid

  10 

November 2021

 $3,250  $1,354  $1,896 

Betaine

  5 

September 2022

  2,125   1,399   726 

Nitisinone

  5 

October 2023

  650   292   358 

GoLike

  10 

March 2024

  1,868   327   1,541 

Increlex

  10 

December 2024

  21,250   2,200   19,050 

Galzin

  10 

December 2024

  8,119   812   7,307 
       $37,262  $6,384  $30,878 
Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Table Text Block]
  

Amortization

 

Year

 

Expense

 

Remainder of 2026

 $2,816 

2027

  5,707 

2028

  5,374 

2029

  5,276 

2030

  5,276 

Thereafter

  21,229 

Total estimated amortization expense

 $45,678